Highlights
NASDAQ: ONCY       Oncolytics Biotech Inc
Last Price Today's Change   Day's Range   Trading Volume
2.167   -0.083 (3.69%)  2.13 - 2.35  528,005

Overview

 
Avg Volume (4 weeks):1,843,557
4 Weeks Range:1.63 - 2.92
4 Weeks Price Volatility (%):
41.63%
52 Weeks Range:0.35 - 6.02
52 Weeks Price Volatility (%):
32.05%
Average Price Target:-

Headlines



No recent Headlines for this stock.


Business Background

Oncolytics Biotech Inc. (Oncolytics) is a development-stage company. The Company is focused on research and development of REOLYSIN, which is its cancer therapeutic. REOLYSIN is developed from reovirus. Oncolytics is directing a clinical trial program with the focus of developing REOLYSIN as a human cancer therapeutic. The clinical program includes clinical trials, which it sponsors directly along with Third Party Clinical Trials. Third Party Clinical Trials are clinical trials that are being sponsored by other institutions. Its clinical trial program includes human trials using REOLYSIN alone, and in combination with radiation and chemotherapy, and delivered via local administration and/or intravenous administration. Oncolytics uses contract toll manufacturers to produce REOLYSIN. The Company has two subsidiaries: Oncolytics Biotech (Barbados) Inc. (OBB), a Barbados company, and Valens Pharma Ltd. Oncolytics Biotech (US) Inc. and Oncolytics Biotech (U.K.) are subsidiaries of OBB.

  Be the first to like this.
 


APPS
I3 Messenger
Individual or Group chat with anyone on I3investor
 
 

3849  1865  360  2881 

ActiveGainersLosers
Top 10 Active Counters
 NameLastChange 
 CIDM 3.82+2.51 
 VISL 0.94+0.515 
 AAL 14.97+3.12 
 GNUS 4.74-3.19 
 XSPA 1.745+0.665 
 NIO 6.14+0.54 
 AVP 5.60-0.05 
 UAL 38.84+5.19 
 DAL 32.23+3.76 
 SAVE 21.51+4.20 
Partners & Brokers